Skip to content

PHARM@21

Active
Private limited companyfounded 200520 yrs activePopulierestraat 80, 9310 Aalst, BelgiumKBO/BCE: BE 0876.529.018
Summary

PHARM@21 has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.1m and a net result of €51,752. Equity is growing by ~7.9% per year across the filed fiscal years. Its solvency ranks better than 48% of 10522 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).

Checked score

Score 2025
Axes · tick = 2024
Profitability54▼-18
Solvency61▲+1
Growth52▼-26
Track record100
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €65,000 at 30 days acceptable
Liquidity short (current ratio 0.04 against 0.49 in 2024; short-term debt: 21.6% and cash: 0.3% of total assets), and 64.3% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 20 years 0 30 y
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
35.7%
Return on assets
1.6%
Age of the figures
18 mo
neutral · Filed after the deadline
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 27-11-2025, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
27 d late
2024
27 d late
2023
29 d late
2022
25 d late
2021
27 d late
2020
30 d late
2019
29 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 28 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today. Usually files around 27 November (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
31-03-2026 close29-09-2026 today31-10-2026 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 6 October 2005, PHARM@21 was incorporated.1 Total assets went from EUR 1.7 million in 2019 to EUR 3.2 million in 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2019 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, abbreviated schema

Equity
€1.1m▲ 5.3%
2024 · €1.1m
Total assets
€3.2m▲ 3.5%
2024 · €3.1m
Net result
€51,752▼ 41.5%
2024 · €88,503
Working capital
-€665,643▼ 63.2%
2024 · -€407,749
Trend over the years

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before
favourable unfavourable
Line20212022202320242025
Operating result€101,645▲ 20.0%€139,626▲ 37.4%€110,796▼ 20.6%€152,256▲ 37.4%€102,350▼ 32.8%
Net result€61,387within the sector's middle half▲ 23.2%€91,826within the sector's middle half▲ 49.6%€72,896within the sector's middle half▼ 20.6%€88,503within the sector's middle half▲ 21.4%€51,752within the sector's middle half▼ 41.5%
Equity€839,751above the sector's middle half▲ 7.9%€931,577above the sector's middle half▲ 10.9%€998,273above the sector's middle half▲ 7.2%€1.1mabove the sector's middle half▲ 8.9%€1.1mabove the sector's middle half▲ 5.3%
Total assets€1.8mabove the sector's middle half▲ 0.7%€2.0mabove the sector's middle half▲ 10.1%€2.7mabove the sector's middle half▲ 34.2%€3.1mabove the sector's middle half▲ 15.5%€3.2mabove the sector's middle half▲ 3.5%
Debt€976,406▼ 4.8%€1.1m▲ 9.3%€1.7m▲ 57.8%€2.0m▲ 19.5%€2.1m▲ 2.5%
Working capital-€391,376below the sector's middle half▲ 37.5%-€390,514below the sector's middle half▲ 0.2%-€367,744below the sector's middle half▲ 5.8%-€407,749below the sector's middle half▼ 10.9%-€665,643below the sector's middle half▼ 63.2%
Solvency46.2%within the sector's middle half▲ 3.1pp46.6%within the sector's middle half▲ 0.4pp37.2%within the sector's middle half▼ 9.4pp35.1%within the sector's middle half▼ 2.1pp35.7%within the sector's middle half▲ 0.6pp
Current ratio0.02below the sector's middle half=0.04below the sector's middle half▲ 0.020.29below the sector's middle half▲ 0.250.49below the sector's middle half▲ 0.200.04below the sector's middle half▼ 0.46
Return on assets (ROA)3.4%within the sector's middle half▲ 0.6pp4.6%within the sector's middle half▲ 1.2pp2.7%within the sector's middle half▼ 1.9pp2.9%within the sector's middle half▲ 0.1pp1.6%within the sector's middle half▼ 1.2pp
above within below the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
€0€50,000€100,000€150,000Operating result 2021: €101,645€101,645Net result 2021: €61,387€61,387Operating result 2022: €139,626€139,626Net result 2022: €91,826€91,826Operating result 2023: €110,796€110,796Net result 2023: €72,896€72,896Operating result 2024: €152,256€152,256Net result 2024: €88,503€88,503Operating result 2025: €102,350€102,350Net result 2025: €51,752€51,75220212022202320242025€0€50,000€100,000€150,000Operating result 2023: €110,796€111,000Net result 2023: €72,896€72,900Operating result 2024: €152,256€152,000Net result 2024: €88,503€88,500Operating result 2025: €102,350€102,000Net result 2025: €51,752€51,800202320242025
The operating result falls in 2025; 2025 is 33% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.2m
Fixed assets €3.2m ▲ 17.8%
Current assets €25,834 ▼ 93.5%
Equity and liabilities €3.2m
Equity €1.1m ▲ 5.3%
Debt €2.1m ▲ 2.5%
Debt's share of the balance-sheet total falls from 64.9% to 64.3%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€145,777▼
2024 · €179,689
Cash flow
€95,180▼
2024 · €115,935
Debt to equity
1.80▼
2024 · 1.85
ROE
4.5%▼
2024 · 8.1%
Interest coverage
3.94▼
2024 · 5.92
Debt ≤ 1 year
€691,477▼
2024 · €806,804
Debt > 1 year
€1.3m▲
2024 · €1.2m
Income taxes
€18,209▼
2024 · €35,483
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 14,732 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 96% are still going.

  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet
0.2% went bankrupt
3.5% stopped otherwise
96% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.6% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.9%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 14,732 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 47 lines
Balance sheet Code20242025
Assets
Total assets20/58€3.1m€3.2m▲
Fixed assets21/28€2.7m€3.2m▲
Tangible fixed assets22/27€1.6m€2.1m▲
Land and buildings22€1.6m€2.1m▲
Plant, machinery and equipment23€1,284€790▼
Furniture and vehicles24€1,311€1,283▼
Financial fixed assets28€1.1m€1.1m=
Current assets29/58€399,055€25,834▼
Amounts receivable within one year40/41€29,098€8,060▼
Other amounts receivable41€29,098€8,060▼
Current investments50/53€130,000-
Cash at bank and in hand54/58€230,942€10,964▼
Deferred charges and accrued income490/1€9,015€6,810▼
Equity and liabilities
Total equity and liabilities10/49€3.1m€3.2m▲
Equity10/15€1.1m€1.1m▲
Contributions10/11-€6,200
Reserves13€1.1m€1.1m▲
Distributable reserves133€1.1m€1.1m▲
Amounts payable17/49€2.0m€2.1m▲
Amounts payable after more than one year17€1.2m€1.3m▲
Financial debts170/4€1.2m€1.3m▲
Amounts payable within one year42/48€806,804€691,477▼
Current portion of amounts payable after more than one year42€115,179€142,678▲
Financial debts43€23,447€20,885▼
Credit institutions430/8€23,447€20,885▼
Trade debts44€604,689€430,797▼
Suppliers440/4€604,689€430,797▼
Taxes, remuneration and social security45€3,531€2,986▼
Taxes450/3€3,531€2,986▼
Other amounts payable47/48€59,959€94,131▲
Accrued charges and deferred income492/3€3,586€22,489▲
Income statement Code20242025
Non-recurring operating income76A€2-
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€27,432€43,427▲
Other operating charges640/8€7,537€77,148▲
Gross operating margin9900€187,225€222,925▲
Operating profit (loss)9901€152,256€102,350▼
Financial income75/76B€2,103€4,619▲
Recurring financial income75€2,103€4,619▲
Financial charges65/66B€30,373€37,008▲
Recurring financial charges65€30,373€37,008▲
Profit (loss) for the period before taxes9903€123,986€69,961▼
Income taxes67/77€35,483€18,209▼
Profit (loss) for the period9904€88,503€51,752▼
Profit (loss) for the period to be appropriated9905€88,503€51,752▼
Appropriation of the result
Profit (loss) to be appropriated9906€88,503€51,752▼
Transfer to equity691/2€88,503€51,752▼
To other reserves6921€88,503€51,752▼

The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20212022202320242025Change
Non-recurring operating income76A---€2--
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€47,927€48,828€36,020€27,432€43,427▲ 58.3%
Other operating charges640/8-€4,583€5,787€7,537€77,148▲ 924%
Gross operating margin9900€154,204€193,037€152,603€187,225€222,925▲ 19.1%
Operating profit (loss)9901€101,645€139,626€110,796€152,256€102,350▼ 32.8%
Financial income75/76B-€0€90€2,103€4,619▲ 120%
Recurring financial income75€0€0€90€2,103€4,619▲ 120%
Financial charges65/66B-€9,632€17,221€30,373€37,008▲ 21.8%
Recurring financial charges65€16,764€9,632€17,221€30,373€37,008▲ 21.8%
Profit (loss) for the period before taxes9903€84,881€129,994€93,665€123,986€69,961▼ 43.6%
Income taxes67/77€23,494€38,167€20,769€35,483€18,209▼ 48.7%
Profit (loss) for the period9904€61,387€91,826€72,896€88,503€51,752▼ 41.5%
Profit (loss) for the period to be appropriated9905€61,387€91,826€72,896€88,503€51,752▼ 41.5%
Line20212022202320242025Change
Assets
Total assets20/58€1.8m€2.0m€2.7m€3.1m€3.2m▲ 3.5%
Fixed assets21/28€1.8m€2.0m€2.5m€2.7m€3.2m▲ 17.8%
Tangible fixed assets22/27€706,562€881,813€1.4m€1.6m€2.1m▲ 30.1%
Land and buildings22-€876,918€1.4m€1.6m€2.1m▲ 30.2%
Plant, machinery and equipment23-€1,192€1,778€1,284€790▼ 38.5%
Furniture and vehicles24-€3,703€2,280€1,311€1,283▼ 2.1%
Financial fixed assets28€1.1m€1.1m€1.1m€1.1m€1.1m=
Current assets29/58€9,594€16,883€151,912€399,055€25,834▼ 93.5%
Amounts receivable within one year40/41--€13,231€29,098€8,060▼ 72.3%
Other amounts receivable41--€13,231€29,098€8,060▼ 72.3%
Current investments50/53---€130,000--
Cash at bank and in hand54/58€4,241€9,303€134,451€230,942€10,964▼ 95.3%
Deferred charges and accrued income490/1-€7,580€4,230€9,015€6,810▼ 24.5%
Equity and liabilities
Total equity and liabilities10/49€1.8m€2.0m€2.7m€3.1m€3.2m▲ 3.5%
Equity10/15€839,751€931,577€998,273€1.1m€1.1m▲ 5.3%
Contributions10/11€6,200€6,200--€6,200-
Capital10-€6,200----
Issued capital100-€18,600----
Uncalled capital101-€12,400----
Reserves13€833,551€925,377€998,273€1.1m€1.1m▲ 4.8%
Non-distributable reserves130/1-€1,860----
Legal reserve130-€1,860----
Distributable reserves133-€923,517€998,273€1.1m€1.1m▲ 4.8%
Amounts payable17/49€976,406€1.1m€1.7m€2.0m€2.1m▲ 2.5%
Amounts payable after more than one year17€562,500€646,786€1.2m€1.2m€1.3m▲ 12.2%
Financial debts170/4-€646,786€1.2m€1.2m€1.3m▲ 12.2%
Amounts payable within one year42/48€400,970€407,397€519,656€806,804€691,477▼ 14.3%
Current portion of amounts payable after more than one year42-€101,429€123,929€115,179€142,678▲ 23.9%
Financial debts43-€16,688€17,362€23,447€20,885▼ 10.9%
Credit institutions430/8-€16,688€17,362€23,447€20,885▼ 10.9%
Trade debts44€6,876€255,198€321,989€604,689€430,797▼ 28.8%
Suppliers440/4-€255,198€321,989€604,689€430,797▼ 28.8%
Taxes, remuneration and social security45-€6,167€3,055€3,531€2,986▼ 15.4%
Taxes450/3-€6,167€3,055€3,531€2,986▼ 15.4%
Other amounts payable47/48-€27,915€53,321€59,959€94,131▲ 57.0%
Accrued charges and deferred income492/3-€12,936€5,286€3,586€22,489▲ 527%
Line20212022202320242025Change
Profit (loss) for the period9904€61,387€91,826€72,896€88,503€51,752▼ 41.5%
+ Depreciation and write-downs630€47,927€48,828€36,020€27,432€43,427▲ 58.3%
Operating cash flow (approximation)€109,314€140,654€108,916€115,935€95,180▼ 17.9%
Investment in fixed assets (approximation)--€224,078-€584,493-€196,577-€525,067▼ 167%
Change in cash-€5,063€125,147€96,492-€219,979▼ 328%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-10-2026
2026
04-09
State Gazette act Appointments: VAN BREMPT Famke, VAN BREMPT Kato and 2 others
Declaration · Power of attorney · Purpose change9 facts ▸
  • Director appointment, VAN BREMPT Famke (bijkomende niet statutaire bestuurder)
  • Director appointment, VAN BREMPT Kato (bijkomende niet statutaire bestuurder)
  • Declaration, 10-08-2026
  • Director appointment, VAN BREMPT Joris Jozef Maria (managing director)
  • Director appointment, VLAEMINCK Tina Irma (managing director)
  • Other statement, coördinatie statuten, opdracht gegeven aan notaris om coördinatie op te maken, te ondertekenen en neer te leggen
  • Power of attorney, Torck
  • General meeting, 27-08-2026
  • Purpose change
2025
27-11
NBB filing Annual accounts filed
fiscal year 2025 · abbreviated schema · 27 days late
2024
27-11
NBB filing Annual accounts filed
fiscal year 2024 · abbreviated schema · 27 days late
31-03
Financial Equity above €1mEq €1.1m ▲8.9%
6 profitable years in a row build equity to €1.1m.
2023
29-11
NBB filing Annual accounts filed
fiscal year 2023 · abbreviated schema · 29 days late
2022
25-11
NBB filing Annual accounts filed
fiscal year 2022 · abbreviated schema · 25 days late
31-03
Financial Highest result since 2019net €91,826 ▲49.6%
Net result €91,826, the highest in the series.
2021
27-11
NBB filing Annual accounts filed
fiscal year 2021 · abbreviated schema · 27 days late
2020
30-11
NBB filing Annual accounts filed
fiscal year 2020 · abbreviated schema · 30 days late
31-03
Financial Weakest financial yearnet €49,818 ▼26.4%
Net result drops to €49,818, the lowest in the series; recovery starts the following year.
2019
29-11
NBB filing Annual accounts filed
fiscal year 2019 · abbreviated schema · 29 days late
2018
30-11
NBB filing Annual accounts filed
fiscal year 2018 · abbreviated schema · 30 days late
2017
31-10
NBB filing Annual accounts filed
fiscal year 2017 · abbreviated schema
2016
30-11
NBB filing Annual accounts filed
fiscal year 2016 · abbreviated schema · 30 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 4 acts read
About the unread acts

Of the 4 Belgian State Gazette acts we know for this company, 1 has been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
under verification, last change in 2026
This board is reconstructed from a single act (26358562). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.

Board 2

Famke VAN BREMPT
Bijkomende niet statutaire bestuurder · since 27-08-2026
Current
Kato VAN BREMPT
Bijkomende niet statutaire bestuurder · since 27-08-2026
Current

Day-to-day management 2

Joris Jozef Maria VAN BREMPT
Managing director · since 27-08-2026
Current
Tina Irma VLAEMINCK
Managing director · since 27-08-2026
Current
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
3 of this company's 4 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Aalst · 1 establishment unit since 2006
seat establishment The establishment unit on the map
Ground area
2,687 m²
Building footprint
152 m²
Volume, LiDAR
870 m³
Parcel 41042E0323/00M000, Flanders · tallest building 7.5 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Pharm@21
Populierestraat 80, 9310 AalstRetail sale of pharmaceutical products
since 20062.152.683.584
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
41042E0323/00M000 Flanders 2,687 m² 1 · 152 m² 7.5 m · 2 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Mandate history

4 people since 2026, 4 in office
Show
  • Board
  • Day-to-day management
Mandates per person, with start and end dates
Name Functions and periods
Famke VAN BREMPT
  • Bijkomende niet statutaire bestuurder, from 27-08-2026 to date
Kato VAN BREMPT
  • Bijkomende niet statutaire bestuurder, from 27-08-2026 to date
Joris Jozef Maria VAN BREMPT
  • Managing director, from 27-08-2026 to date
Tina Irma VLAEMINCK
  • Managing director, from 27-08-2026 to date
See the board, name and seat on a given date →

Articles of association

Purpose
Optimaliseren van vermogen; Het oprichten, het promoveren} valoriseren, inrichten, uitrusten, exploiteren en beheren van beboude of onbebouwde onroerende goederen en van…
Full purpose (10 activities)
  1. Optimaliseren van vermogen
  2. Het oprichten, het promoveren} valoriseren, inrichten, uitrusten, exploiteren en beheren van beboude of onbebouwde onroerende goederen en van lichamelijke of onlichamelijke roerende goederen , met inbegrip van de handel onder al zijn vormen in die goederen; zo ondermeer:
  3. Het verstrekken van raad en bijstand aan ondernemingen; het beoefenen, adviseren en participeren in de industriële-en handelssector; het optreden als tussenpersoon bij overname van ondernemingen;
  4. Het aan-en verkopen, oprichten, uitrusten, bouwen, valoriseren, huren en verhuren van alle onroerende goederen, kortom het realiseren van onroerend goed transacties voor eigenrekening;
  5. Het aan- en verkopen van evenals inschrijven op en deelnemen aan alle mogelijke roerende waarden en effecten die worden uitgegeven door ondernemingen of door overheden;
  6. Het ontwikkelen, verwerven, verhandelen of in licentie geven van octrooien, patenten, know-how, merken en modellen, kortom alle soorten intellectuele rechten en aanverwante immateriële vaste activa, al dan niet met het verrichten van wetenschappelijk onderzoek dat daarop betrekking heeft;
  7. Bij wijze van inbreng in natura of in speciën op gelijke welke wij ze participeren in alle bestaande of op te richten rechtspersonen in Belgie of in het buitenland, al dan niet met een gelijk voorwerp als het hare evenals het waarnemen van het bestuur of als vereffenaar, toezicht en controle in alle vennootschappen, waarmee al dan niet een band van deelneming bestaat evenals het verstrekken van zakelijke en/of persoonlijke zekerheden en kredieten, met uitzondering van elke financiële verrichting onder welke vorm ook die valt onder het toezicht van de commissie voor het Bank-, Financie- en Assurantiewezen.
  8. Het opzoeken, selecteren, recruteren van personeel voor ondernemingen;
  9. Het lanceren van nieuwe producten en ontwikkelingsprojecten;
  10. Het uitvoeren van marketing-enquêtes, promotionele en verkoopacties alsmede het creëren, lanceren, begeleiden van nieuwe markten voor ondernemingen.

Structure & network

Owners and holdings

1 holding

Owners 0

The accounts to 31-03-2025 list no shareholders, and no other source names one.

Holdings 1

According to the annual accounts to 31-03-2025 of PHARM@21 and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

4 current directors
Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Public money · subsidies and aid

Flemish government

2025 · 1 entry · 2,004 EUR awarded · 2,004 EUR paid
Year Entries awardedpaid
2025 1 2,004 EUR2,004 EUR
Schemes
1 entry · 2,004 EUR · 2,004 EUR paid · Vlaams Energie- en Klimaatagentschap

Similar companies · same sector, comparable size

Of 5,220 companies in sector 47730 we hold annual accounts for 3,862. 2,916 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded06-10-2005
Fiscal year end31-03
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
81300Landscape service activities
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
47750Retail sale of cosmetics and toilet articles
70200Business and other management consultancy
82990Other business support services
86999Other human health activities
E-invoicing
Reachable via Peppol
Peppol ID 0208:0876529018
Also 9925:BE0876529018
Registered 30-08-2023

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.